Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease.
Kawanaka M, Kamada Y, Takahashi H, Iwaki M, Nishino K, Zhao W, Seko Y, Yoneda M, Kubotsu Y, Fujii H, Sumida Y, Kawamoto H, Itoh Y, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Kawanaka M, et al. Among authors: seko y. Gastro Hep Adv. 2024 Aug 14;3(8):1120-1128. doi: 10.1016/j.gastha.2024.08.008. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39533978 Free PMC article.
Artificial Intelligence and Machine Learning Predicting Transarterial Chemoembolization Outcomes: A Systematic Review.
Cho EEL, Law M, Yu Z, Yong JN, Tan CS, Tan EY, Takahashi H, Danpanichkul P, Nah B, Soon GST, Ng CH, Tan DJH, Seko Y, Nakamura T, Morishita A, Chirapongsathorn S, Kumar R, Kow AWC, Huang DQ, Lim MC, Law JH. Cho EEL, et al. Among authors: seko y. Dig Dis Sci. 2024 Dec 21. doi: 10.1007/s10620-024-08747-5. Online ahead of print. Dig Dis Sci. 2024. PMID: 39708260
Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.
Ishiba H, Fujii H, Kamada Y, Sumida Y, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Fukushima H, Miyoshi E, Aishima S, Itoh Y, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Ishiba H, et al. Among authors: seko y. Hepatol Commun. 2024 Dec 11;9(1):e0563. doi: 10.1097/HC9.0000000000000563. eCollection 2025 Jan 1. Hepatol Commun. 2024. PMID: 39670882 Free PMC article.
Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol.
Iwaki M, Kobayashi T, Nogami A, Ogawa Y, Imajo K, Sakai E, Nakada Y, Koyama S, Kurihashi T, Oza N, Kohira T, Okada M, Yamaguchi Y, Iwane S, Kageyama F, Sasada Y, Matsushita M, Tadauchi A, Murohisa G, Nagasawa M, Sato S, Maeda K, Furuta K, Shigefuku R, Seko Y, Tobita H, Kawata K, Kawanaka M, Sugihara T, Tamaki N, Iwasa M, Kawaguchi T, Itoh Y, Kawaguchi A, Takahashi H, Nakajima A, Yoneda M. Iwaki M, et al. Among authors: seko y. BMJ Open. 2024 Nov 24;14(11):e088862. doi: 10.1136/bmjopen-2024-088862. BMJ Open. 2024. PMID: 39581726 Free PMC article. Clinical Trial.
Differential Prognostic Impact of Clinical Congestion between Preserved versus Reduced Ejection Fraction in Patients Hospitalized for Acute Decompensated Heart Failure: Findings from the Japanese Kyoto Congestive Heart Failure Registry.
Nagao K, Kato T, Yaku H, Morimoto T, Aida K, Maruichi SK, Inuzuka Y, Tamaki Y, Yamamoto E, Yoshikawa Y, Kitai T, Taniguchi R, Iguchi M, Kato M, Takahashi M, Jinnai T, Kawai T, Komasa A, Nishikawa R, Kawase Y, Morinaga T, Su K, Kawato M, Seko Y, Inada T, Inoko M, Toyofuku M, Furukawa Y, Nakagawa Y, Ando K, Kadota K, Shizuta S, Sato Y, Kuwahara K, Ozasa N, Ono K, Kimura T. Nagao K, et al. Among authors: seko y. J Card Fail. 2024 Sep 30:S1071-9164(24)00413-5. doi: 10.1016/j.cardfail.2024.08.060. Online ahead of print. J Card Fail. 2024. PMID: 39357667 Free article.
360 results